Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)

Revista Brasileira de Psiquiatria

Volumn 32, Issue 1, 2010, Pages 56-61

  Hallak, Jaime E C ^a,b   Machado de Sousa, João Paulo ^a,b   Crippa, José Alexandre S ^a,b   Sanches, Rafael Faria ^a,b   Trzesniak, Clarissa ^a,b   Chaves, Cristiano ^a,b   Bernardo, Sandra Aparecida ^a   Regalo, Simone Cecílio ^a,b   Zuardi, Antonio Waldo ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Instituto Nacional de Ciência e Tecnologia Translacional em Medicina CNPq   (Brazil)

Author keywords

Cannabidiol; Cognition; Psychotic disorders; Schizophrenia

Indexed keywords

CANNABIDIOL; PLACEBO;

ADULT; ARTICLE; AUDITORY STIMULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; ELECTRODERMAL RESPONSE; FEMALE; HUMAN; MALE; MENTAL PATIENT; NEUROPSYCHOLOGICAL TEST; SCHIZOPHRENIA; SELECTIVE ATTENTION; STIMULUS RESPONSE; STROOP COLOR WORD TEST; TASK PERFORMANCE;

EID: 77950542042     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-44462010000100011     Document Type: Article

References (40)

1. Moreau J. Hashish and Mental Illness. New York (NY): Raven Press; 1973.
2. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34(5):605-613
3. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry. 2001;178:101-106
4. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946-1949
5. Kovasznay B, Fleisher J, Tanenberg-Karant M, Miller AD, Bromet E. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull. 1997;23(2):195-201.
6. Andréasson S, Allebeck P, Engström A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 1987;2(8574):1483-1486
7. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 1999;10(8):1665-1669
8. Emrich HM, Leweke FM, Schneider U. Towards a cannabinoid hypothesis of schizophrenia: Cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav. 1997;56(4):803-807
9. Glass M. The role of cannabinoids in neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25(4):743-765
10. Leweke FM, Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict Biol. 2008;13(2):264-275
11. Karniol IG, Carlini EA. Pharmacological interaction between cannabidiol and delta 9-tetrahydrocannabinol. Psychopharmacologia. 1973;33(1):53-70.
12. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and others effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl). 1982;76(3):245-250
13. Zuardi AW, Teixeira NA, Karniol IG. Pharmacological interaction of the effects of delta 9-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats. Arch Int Pharmacodyn Ther. 1984;269(1):12-19
14. Zuardi AW, Antunes-Rodrigues J, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology. 1991;104(2):260-264
15. Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM. Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav. 2000;66(1):175-181
16. Zuardi AW, Crippa JAS, Hallak JEC, Moreira FA, Guimarães FS. Cannabidiol as an antipsychotic drug. Braz J Med Biol Res. 2006;39:421-429
17. Zuardi AW, Morais SL, Guimarães FS, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry. 1995;56(10):485-486
18. Leweke FM, Koethe D, Gerth CW, Nolden BM, Schreiber D, Gross S, Schultze-Lutter F, Hellmich M, Klosterkotter J. Cannabidiol as an antipsychotic agent. 2005 Symposium on the Cannabinoids. Eur Psychiatry. 2007;22(Suppl 1):S21.
19. Zuardi AW, Guimarães FS, Guimarães VNC, Delben EA. Cannabidiol. In: Grotenhermen F, editor. Cannabis und Cannabinoide. Bern: Verlag Hans Huber; 2001. p.381-393
20. Carter CS, Mintum M, Nichols T, Cohen JD. Anterior cingulate gyrus disfunction and selective deficits in schizophrenia: [15O]H2O PET study during single-trial Stroop task performance. Am J Psychiatry. 1997;154(12):1670-1675
21. Hyman SE, Fenton WS. What are the right targets for psychopharmacology? Science. 2003;299(5605):358-359
22. Green MF, Nuechterlein KH. Should schizophrenia be treated as a neurocognitive disorder? Schizophr Bull. 1999;25(2):309-319
23. Grapperon J, Delage M. Stroop test and schizophrenia. Encephale. 1999;25(l):50-58
24. Crippa, JAS, Hallak JEC, Sanches RF, Lopes-Machado EZL, Guimarães FS, Heten LA, Zuardi AW. Alterações eletrodérmicas na esquizofrênia. J Bras Psiquiatr. 2001;50(7-8):255-264
25. Lopes-Machado EZ, Crippa JA, Hallak JE, Guimarães FS, Zuardi AW. Electrodermically nonresponsive schizophrenia patients make more errors in the Stroop Color Word Test, indicating selective attention deficit. Schizophr Bull. 2002;28(3):459-466
26. First MB, Spitzer RL, Gibbon M, Williams JB. Structured clinical interview for DSM-IV axis I disorders - clinician version (SCID-CV). Washington (DC): American Psychiatric Press; 1997.
27. Overall JE, Gorham DR. The brief psychiatric rating scale. Psycol Rep. 1962;10:799-812.
28. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276
29. Liddle PF, Morris D. Schizophrenic syndromes and frontal lobe performance. Br J Psychiatry. 1991;158:340-345
30. Chaves AC, Shirakava I. Escala das síndromes negativa e positiva - PANSS e seu uso no Brasil. Rev Psiquiatr Clin. 1998;25:337-343
31. Bernstein AS, Frith CH, Gruzelier JH, Patterson T, Straube E, Venables PH, Zahn TP. An analysis of the skin conductance orienting response in samples of American, British, and German schizophrenics. Biol Psychol. 1982;14(3-4):155-211.
32. Dawson ME, Nuechterlein KH, Schell AM, Gitlin M, Ventura J. Autonomic abnormalities in schizophrenia - State or trait indicators? Arch Gen Psychiatry. 1994;51:813-824
33. Chen EYH, Wong AWS, Chen RYL, Au JWY. Stroop interference and facilitation effects in first-episode schizophrenic patients. Schizophr Res. 2001;48(1):29-44.
34. Baxter RD, Liddle PF. Neuropsychological deficits associated with schizophrenic syndromes. Schizophr Res. 1998;30(3):239-249
35. Perlstein WM, Carter CS, Barch DM, Baird JW. The Stroop task and attention deficits in schizophrenia: a critical evaluation of card and single-trial Stroop methodologies. Neuropsychology. 1998;12(3):414-425
36. Monti JM. Hypnotic-like effects of cannabidiol in the rats. Psychopharmacology (Berl). 1977;55(3):263-265
37. Pickens JT. Sedative activity of cannabis in relation to its D9-tetrahydrocannabinol and cannabidiol content. Br J Pharmacol. 1981;72(4):649-656
38. Carlini EA, Masur J, Magalhães CCPB. Possível efeito hipnótico do canabidiol no ser humano. Estudo preliminar. Ciênc Cult (São Paulo). 1979;31:315-322
39. Brodkin J, Moerschbaecher, JM. SR141716 antagonizes the disruptive effects of cannabinoid ligands on learning in rats. J Pharmacol Exp Ther. 1997;282(3):1526-1532
40. Thomas BF, Gilliam AF, Burcj DF, Roche MJ, Setzman HH. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther. 1998;285(1):285-292